United States - English - NLM (National Library of Medicine)

apotex corp. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 3 mg in 1 ml - ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli, pseudomonas aeruginosa, and staphylococcus aureus. chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis , pseudomonas aeruginosa, and staphylococcus aureus . acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae, moraxella catarrhalis , pseudomonas aeruginosa, staphylococcus aureus, and streptococcus pneumoniae . ofloxacin otic solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

larken laboratories, inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. please see dosage and administration for specific recommendations. acute bacterial exacerbations of chronic bronchitis (abecb) due to haemophilus influenzae or streptococcus pneumoniae . because fluoroquinolones, including

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 3 mg in 1 ml - ofloxacin otic solution, 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli , pseudomonas aeruginosa and staphylococcus aureus . chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis , pseudomonas aeruginosa and staphylococcus aureus . acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae , moraxella catarrhalis , pseudomonas aeruginosa , staphylococcus aureus and streptococcus pneumoniae . ofloxacin otic solution, 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli, pseudomonas aeruginosa, and staphylococcus aureus. chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis , pseudomonas aeruginosa, and staphylococcus aureus . acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae, moraxella catarrhalis , pseudomonas aeruginosa, staphylococcus aureus, and streptococcus pneumoniae . ofloxacin otic solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

nivagen pharmaceuticals, inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, usp and other antibacterial drugs, ofloxacin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ofloxacin tablets, usp are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. please see dosage and administration for specific recommendations. acute bacterial exacerbations of chronic bronchitis (abecb) due to haemophilus influenzae or streptococcus pneumoniae . because fluoroquinolones, including ofloxacin, have been as